Axsome Therapeutics (AXSM) Depreciation & Amortization (CF) (2015 - 2026)

Axsome Therapeutics has disclosed Depreciation & Amortization (CF) across 12 years of filings, most recently posting $116000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $116000.0, down 22.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $470000.0 (down 14.39% YoY), and the FY2025 annual result was $503000.0, down 5.45% from the prior year.
• Depreciation & Amortization (CF) came in at $116000.0 for Q1 2026 at Axsome Therapeutics, up from $114000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $149000.0 in Q1 2025 to a low of $37000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $120000.0 (2025), against an average of $110176.5.
• Across the five-year window, Depreciation & Amortization (CF) soared 587.25% in 2022 and declined 22.15% in 2026, its largest moves.
• Axsome Therapeutics' Depreciation & Amortization (CF) stood at $85000.0 in 2022, then soared by 56.47% to $133000.0 in 2023, then declined by 3.01% to $129000.0 in 2024, then dropped by 11.63% to $114000.0 in 2025, then rose by 1.75% to $116000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $116000.0 (Q1 2026), $114000.0 (Q4 2025), and $120000.0 (Q3 2025), per Business Quant data.